Events

The 5th Circular and Self-Amplifying RNA Therapeutics Summit is the only industry forum dedicated exclusively to translating circRNA and saRNA into durable, IND-ready medicines. As the RNA field moves beyond linear mRNA, these next-generation modalities are emerging as the solution to short-lived expression, high dosing requirements, and limited therapeutic reach. With first-in-human trials now underway, increasing regulatory engagement, and expanding applications across oncology, autoimmune disease, and in vivo CAR-T, 2026 represents a critical inflection point. Developers must now prove not just promise, but performance, from durability and immunogenicity control to delivery, manufacturability, and IP strategy. Held in Boston from May 26–28, 2026, this summit brings together senior leade…

The UK Biotech Day is a leading event for the UK life sciences sector, bringing together executives and R&D scientists from pharma, biotech, medtech, techbio, investors, lawyers, patent attorneys, CROs, CDMOs, accountants, bankers, executive search agencies and others. Serving as a global gateway, it also connects the UK ecosystem with international partners to drive strategic collaborations through dealmaking, innovation, networking and finding new clients and partners.

The Digi-Tech Pharma & AI 2026 Conference is a leading platform uniting pharmaceutical and technology leaders, healthcare innovators, regulatory authorities and solution providers to explore the evolving digital landscape in pharma. This conference promotes collaboration and knowledge exchange, enabling organizations to embrace innovation, streamline operations, and drive better patient outcomes.This event serves as a dynamic platform to explore the integration of science and technology within the pharmaceutical industry, with a strong emphasis on digital trends, AI and machine learning, digital health ecosystems, collaborative innovation, and patient-centric drug development. Key focus areas include digital drug discovery, clinical trials, data science, big data, informatics, real…

The Global Clinical Trials Connect Conference is a premier platform bringing together global leaders, clinical researchers, regulatory experts, and technology pioneers to discuss the latest innovations, best practices, and challenges in clinical trials. This conference fosters collaborations between industry stakeholders to enhance trial efficiency, regulatory compliance, patient safety, and technological adoption.This event unites experts across the clinical trial ecosystem to drive meaningful conversations on digital transformation, decentralized trials, regulatory pathways, patient engagement, and data-driven insights that are shaping the next era of clinical researchFrom adaptive trial designs to AI-powered analytics, this conference explores the latest trends, breakthrough technol…

The Patient Support Programs Canada conference is the premier event for professionals dedicated to advancing patient care and optimizing support programs across the Canadian healthcare landscape. Taking place on June 1-2, 2026 at The Omni King Edward Hotel in Toronto, ON, this highly anticipated event brings together thought leaders and stakeholders from across the bio/pharma industry. Why Attend?Patient Support Programs (PSPs) are a critical component of the healthcare ecosystem and continue to expand in complexity and strategic importance. This conference addresses the need for Canadian organizations to strengthen compliance, governance, and measurement of their PSPs, while continuing to improve access and patient experience, by uniting likeminded professionals for focused, practical dis…

The Marcus Evans 12th Edition Human Factors and User Experience for Medical Device Design conference taking place in San Diego between June 2-3, will explore risk-based usability assessments, regulatory compliance strategies, AI-driven design enhancements, and human-centered innovation to improve user experience in medical devices. Through expert-led panels, real-world case studies, and interactive workshops, industry leaders will share insights on usability testing, risk mitigation, user-centered design, and digital health integration. Our expert speakers will delve into strategies to enhance product usability, streamline regulatory approvals, or optimize user experience. This event provides the latest strategies, tools, and innovations to advance human factors and UX in medical device de…

Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies. Uniting ALS Biotech, Pharma and Academia to Accelerate the Next Generation of ALS and FTD Therapeutics. Strategic moves across the sector-from Eli Lilly's Alchemab-backed ALS expansion to BMS and insistro's genetically driven collaboration and Clene Nanomedicine's regulatory-stage program-underscore the ALS community’s continued commitment to advancing impactful therapies, even in the face of clinical setbacks. With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.…

Achieving precise extrahepatic delivery remains one of the biggest challenges in the LNP field. However, with AbbVie’s acquisition of Capstan Therapeutics and BMS’s acquisition of Orbital Therapeutics, the industry’s confidence in targeted LNPs has never been higher! Returning to Boston in June 2026, the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit is bringing together industry pioneers and leading delivery experts to showcase the latest advances in novel targeting ligands and innovative lipid-based technologies. Across 3 jam-packed days, attendees will gain in-depth technical insights into accelerating the delivery of mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, adipose tissues, muscle, and more. With world-class speaker…

Establish Procurement Excellence for R and D Innovation, Drive Supplier Value and Accelerate Study Timelines Through AI and Strategic Initiatives. R and D procurement is undergoing a major transformation as organizations shift from transactional buying to strategic, innovation-driven value creation across the development pipeline. Procurement teams are navigating unprecedented complexity: strengthening global sourcing models amid geopolitical instability, extracting true value from CRO and CMO partnerships, integrating AI and orchestration tools to streamline operations, and aligning internal stakeholders around business continuity, speed, and scientific ambition. At the same time, the demands of emerging modalities, digital trial technologies, and evolving supplier ecosystems require more…

Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference! Join us in June 2026 as SAE Media Group's renowned West Coast event returns, bringing together biotech pioneers, pharma leaders, and device innovators to shape the future of injectable drug delivery. This year's conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma, device developers, and regulators. What You'll Gain: Actionable insights to strengthen your drug-device portfolio.Opportunities to network with key players shaping the injectable drug delivery landscape.A future-focused perspective…

Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. At the same time, the field is rapidly evolving beyond first-generation designs, with innovations in co-stimulation, conditional activation, multispecific engineering, and affinity tuning aimed at deepening response rates while mitigating dose-limiting toxicities. Innovation is rife within Korea, with companies such as ABL Bio, Novelty Nobility, ABION, and IM Biologics capturing international attention and investment, positioning Korea as a key player in the bispecific and TCE revolution. To accelerate this momentum, the inaugural World Bispecific and T-…

In 2025, cell and gene therapy reached a pivotal moment. Amid rising tariffs, shifting regulations, and capacity constraints, the industry gained clarity on what it takes to scale successfully. As a result, the focus on scaling novel therapies safely and efficiently has never been stronger, introducing a new era of operational excellence and expanded patient access. As we enter 2026, AI, digitalization, and IoT are transforming how cell and gene therapies are planned, tracked, and delivered end-to-end. With smarter, data-driven decision-making, supply chain teams can better navigate tariff fluctuations, manufacturing variability, and regulatory complexity. Designed by and for supply chain leaders across biopharma, including Roche, Bristol Myers Squibb, Johnson and Johnson, Genentech, ProKi…

The 5th World ADC Summit South Korea (9-11 June 2026 | Seoul) is Asia's premier meeting dedicated to accelerating next-generation antibody drug conjugate (ADC) development. As part of the broader World Targeted Therapeutics Summit South Korea, it sits alongside the World TPD and Induced Proximity Summit South Korea and the World Bispecifics and T-Cell Engager Summit South Korea, creating a unified hub for cutting-edge targeted therapeutics innovation. The event brings together more than 300 experts from Korean and global biopharma to address the country's rapid shift from biosimilars toward high-value, first- and best-in-class ADCs. With novel payloads, dual-payload platforms, bispecific ADCs, and strategies to overcome Topo-1 resistance at the forefront, the summit provides end-to-end ins…

Session DescriptionVisualizing the extracellular matrix (ECM) in real-time has long been a challenge. Dr. Kayvon Pedra’s group has developed a novel, cell-impermeant fluorophore that red-shifts and activates upon binding glycans. This allows for seamless, wash-free imaging of glycosylated ECM architecture—from in vitro models to in vivo mouse tumors—providing a powerful new tool for live fluorescence microscopy. Highlights of the presentationA cell-impermeable small molecule fluorophore turns on and red-shifts upon binding glycosylated biomolecules.Application of the dye to live biological samples enables wash-free visualization of extracellular matrix structure.Observations demonstrate no toxicity, a broad substrate profile, deep tissue penetration, and negligible photobleaching in a vari…

17th Annual Clinical Trials Summit 2026   “Bridging Innovation & Integrity: Shaping the Future of Patient-Centric Clinical Trials”   10th & 11th June 2026, World Trade Center (WTC), Mumbai   The 17th Annual Clinical Trials Summit 2026 will serve as a premier platform to explore future advancements in clinical trials and research. The multidisciplinary program brings together professionals from across the clinical research ecosystem to discuss trial planning, management, and emerging innovations. The summit fosters collaboration among industry, academia, patient advocacy groups, and regulatory bodies to address real-world challenges in trial design, data analysis, and execution. Through focused discussions on innovative strategies, new technologies, and quality partne…

NHS ConfedExpo 2026 is the UK’s leading health and care conference, dedicated to improving care for patients and the public. Join over 6,800+ health and care professionals, leaders, and partners for two days of collaboration, insight, and innovation. This is your opportunity to influence the future of health and care, share good practice, and discover solutions that deliver high-quality care for all. Be a part of the conversation shaping the future of health and care.

Recent advances in chemical biology and protein engineering are expanding the boundaries of which proteins can be modulated pharmacologically. Multifunctional small molecules (such as molecular glues, targeted protein degraders, and allosteric modulators) are enabling precise control over protein stability, localization and activity, often by exploiting endogenous cellular pathways. In parallel, novel biologic modalities, including engineered antibodies, multi-specific binders, peptide scaffolds, nucleotide and RNA therapeutics, offer complementary strategies to engage complex or transient target surfaces with high affinity and specificity. Collectively, these approaches are reshaping early‑stage drug discovery by providing versatile platforms to modulate challenging targets through m…

The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and a new wave of next-generation solid tumor and autoimmune programs moving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy. Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology…

Gain practical insight, fresh perspective and real-world learning to help you navigate the next phase of clinical coding with confidence. This focused, one-day, face-to-face forum brings together NHS clinical coding professionals to share proven approaches, lessons learned and strategies you can apply immediately within your own service. Previous attendees consistently highlight the value of this annual conference for its practical relevance, knowledgeable speakers and opportunities to connect with peers facing similar challenges. Through expert presentations, shared NHS experience, interactive discussion and networking, you will leave with clearer direction on ICD-11 and OPCS-4.11, stronger approaches to workforce and hybrid working challenges, improved understanding of data quality for d…